According to the present knowledge, a fraction of HIV-1 infected individuals are able to generate broadly reactive neutralizing activity (brNA) after 2-4 years of infection and, in very rare occasions, close to the first year post-seroconversion. However, brNA has not been described in acute/recent HIV-1 infection.
In this study, serum samples from 157 antiretroviral-naïve individuals within the first year of documented HIV-1 infection were tested in triplicate at a 1/200 dilution against a minipanel of 6 recombinant viruses from 5 different subtypes and different tropisms. The epitopes recognized by the antibodies present in these sera have been characterized by ELISAs, neutralization and competition assays. Samples with cross-reactive neutralization profile, within the first 6 months of infection, were then tested against an extended panel of 20 pseudoviruses (2 tier 3, 14 tier 2 and 4 tier 1) from 4 different subtypes and recombinant forms to confirm brNA.
Detectable brNA was observed in sera from 21 patients (13%) with less than one year of infection with no significant neutralization of the vesicular stomatitis virus (VSV) pseudotyped control. In these patients, neutralization breadth was positively associated with time post-infection (p=0.0001) but, contrary to what has been reported for chronic HIV-1 infection, no association with the level of viremia was observed. The characterization of the epitopes recognized by sera from patients with brNA in recent infection showed a predominant targeting of envelope epitopes within the V2 glycan dependent region. Remarkably, we were able to identify 5 individuals, within the first six months of infection (2 as early as 77 and 96 days post-infection), capable to neutralize viruses from 4 different subtypes and 2 circulating recombinant forms with a geometric mean ID50 titer between 100 and 800.
These results indicate that the induction of broadly reactivity neutralizing responses, despite being rare, is feasible in recently HIV-1 infected individuals. This data should encourage the search for immunogens able to elicit this kind of responses in a preventive HIV-1 vaccine.